After excluding the BRCA2 p.Glu1308Ter carrier (blind control), which was properly identified, four probands in 48 (8.3%) were found to carry a pathogenic variant in a non-BRCA breast cancer gene (Table 1). This evidence concerns the gene BRCA2 and breast cancer.